Saturday 17 October 2026 Export QNRX’s income statement to Excel — free account

Quoin Pharmaceuticals, Ltd. Sponsored ADR

In the quarter to June 2026, EPS grew 69.8% and free cash flow fell 510.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.90 0.13 −3.23%

Follow QNRX

Alert me

Market cap: $8.1M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.28

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	4	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 95.06%

Capital & Financial Ratios $m

Market Cap 8.10

Revenue —

Net Income (18.67)

Free Cash Flow (15.27)

Net Debt (10.80)

Current Ratio 1.76

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 2.81

Past 5Y EPS Growth —

This Y EPS Growth 56.84%

Next Y EPS Growth 59.08%

Next Y revenue growth —

Next 5Y EPS Growth 59.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 53.06%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11	14	19	11
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	11	15	20	12

	2023	2024	2025	Q'26
Payables	1	1	1	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	4	4	6	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	17.17%	0.00%	20.99%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	—	—	—
’25	(3)	(4)	(2)	(5)	(14)
’24	(1)	(2)	(2)	(2)	(8)
’23	(2)	(2)	(1)	(3)	(8)
’22	(2)	(2)	(2)	(2)	(8)
’21	0	(1)	(1)	(3)	(6)
’20	(1)	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	—	—	—
’25	(3)	1	(2)	(5)	(14)
’24	(1)	6	(2)	(2)	(8)
’23	(2)	(2)	(1)	(3)	(8)
’22	(2)	(2)	(2)	(2)	(9)
’21	(1)	(1)	(1)	(3)	(6)
’20	(1)	0	0	(1)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.77)	(1.90)	—	—	—
’25	(6.50)	(6.28)	(6.71)	(14.80)	(14.80)
’24	(38.81)	(13.64)	(16.43)	(12.24)	(66.78)
’23	(142.71)	(74.48)	(68.18)	(72.73)	(337.06)
’22	(1.05k)	(1.36k)	(394.56)	(172.10)	(1.64k)
’21	(6.82k)	(9.02k)	(2.46k)	(11.68k)	(28.44k)
’20	(4.62k)	(14.48k)	(2.52k)	(8.19k)	(3.66k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	241,500.00	308,700.00	220,500.00	33,180.00	8,400.00	8,925.00	466.20	127.40	14.88	5.01	Analyst estimates 2026–2028 Powerpack
	High	562,800.00	1,417,500.00	1,417,500.00	402,150.00	144,690.00	186,480.00	12,337.50	1,184.40	216.30	41.80
People
People	Employees	18	24	28	14	12	4	4	4	5	6
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(4)	(8)	(5)	(5)	(2)	(21)	(9)	(9)	(9)	(16)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(4)	(8)	(5)	(5)	(2)	(21)	(9)	(9)	(9)	(16)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(0.87)	(1.45)	(0.83)	(48,271.06)	(3,659.81)	(28,437.95)	(1,637.02)	(337.06)	(66.78)	(14.80)
	Cash flow	(0.82)	(0.92)	(0.97)	(58,840.00)	(2,231.00)	(7,150.12)	(1,462.19)	(304.82)	(59.62)	(12.68)
	Capex	(0.07)	(0.01)	(0.03)	(340.00)	(361.67)	(781.25)	(43.10)	0.00	0.00	0.00
	Free cash flow	(0.89)	(0.93)	(1.00)	(59,180.00)	(2,592.67)	(7,931.37)	(1,505.29)	(304.82)	(59.62)	(12.68)
	Book value	1.63	0.97	0.57	42,930.00	(11,012.17)	821.25	1,277.03	219.53	69.84	12.28
	Shares, m	5	6	6	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(4)	(5)	(6)	(6)	(1)	(6)	(8)	(8)	(8)	(14)
	Capex	0	0	0	0	0	(1)	0	—	—	—
	Free cash flow	(4)	(5)	(6)	(6)	(2)	(6)	(9)	(8)	(8)	(14)
Balance, $m
Balance, $m	Working capital	8	7	4	4	(8)	4	10	8	11	14
	Total debt	0	—	—	0	1	—	—	—	—	—
	Net debt	(8)	(8)	(5)	(5)	1	(7)	(13)	(11)	(14)	(19)
	Shareholders’ equity	7	5	4	4	(7)	1	7	6	9	13
Returns, %
Returns, %	ROA	(65.07)	(92.62)	(75.23)	(83.30)	(55.53)	(399.87)	(79.33)	(65.25)	(64.30)	(87.56)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(78.87)	(126.74)	(117.27)	(121.45)	181.08	721.40	(234.30)	(132.92)	(120.56)	(141.59)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IMRN IMMURON	$8.3M	— (loss-making)	—	+757.00% (above 0%: growing)	+12.00% (above 0%: growing)	+42.55% (above 0%: growing)	72.16%	0.00%	Compare
ADIL Adial Pharmaceuticals, Inc.	$8.3M	— (loss-making)	—	—	n/m	−263.66% (below 0%: shrinking)	0.00%	0.00%	Compare
BOLT Bolt Biotherapeutics, Inc.	$8.2M	— (loss-making)	— (loss-making)	−99.72% (below 0%: shrinking)	n/m	+38.87% (above 0%: growing)	100.00%	(167,480.00%)	Compare
SNTI Senti Biosciences, Inc.	$8.1M	— (loss-making)	— (loss-making)	−98.68% (below 0%: shrinking)	n/m	−7.48% (below 0%: shrinking)	100.00%	(85,229.41%)	Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR	$8.1M	— (loss-making)	—	—	n/m	−510.28% (below 0%: shrinking)	0.00%	0.00%
XTLB XTL Biopharmaceuticals Ltd.	$8.1M	— (loss-making)	—	−39.32% (below 0%: shrinking)	n/m	+46.78% (above 0%: growing)	0.00%	0.00%	Compare
KPTI Karyopharm Therapeutics Inc.	$8.0M	— (loss-making)	— (loss-making)	−11.86% (below 0%: shrinking)	n/m	−33.34% (below 0%: shrinking)	96.75%	(67.38%)	Compare
CNSP CNS Pharmaceuticals, Inc.	$7.9M	— (loss-making)	—	—	n/m	+33.70% (above 0%: growing)	0.00%	0.00%	Compare
APRE Aprea Therapeutics, Inc.	$7.8M	— (loss-making)	— (loss-making)	−98.40% (below 0%: shrinking)	n/m	−5.22% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$8.1M	—	—	−68.86%	—	+14.24%	84.46%	0.00%

All 614 Biotechnology stocks →

Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX) key facts

Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, QNRX traded at $3.90, a market capitalization of $8.1 million.
Return on equity was −141.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.